Početna › Multipli mijelom › Florida › Miami
Kliničke studije za Multipli mijelom u gradu Miami, FL
Jedna studija za Multipli mijelom traži sudionike na lokaciji u gradu Miami ili blizu njega. Otvorite je da biste vidjeli tko se može priključiti i kako kontaktirati tim studije.
Službeni tekst studije (engleski)
Tražite sudionike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
U tijeku regrutacijaFaza 1/2
- University of Miami, Miami
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
U tijeku regrutacijaFaza 2
- University of Miami Sylvester Comprehensive Cancer Center, Miami
- University of Miami/Sylvester Cancer Institute - Alex's Place, Miami
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building, Miami
- i još 2
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
U tijeku regrutacijaFaza 2
- University of Miami, Miami
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
U tijeku regrutacijaFaza 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- Miami Cancer Institute at Baptist Health, Inc., Miami
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
U tijeku regrutacijaFaza 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
- i još 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
U tijeku regrutacijaFaza 3
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics, Miami
- Sylvester Comprehensive Cancer Center - Kendall, Miami
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
U tijeku regrutacijaFaza 2
- University of Miami, Miami
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- University of Miami Don Soffer Clinical Research Center, Miami
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
U tijeku regrutacijaFaza 1/2
- Research Site, Miami
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
U tijeku regrutacijaFaza 1
- University of Miami, Miami
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
U tijeku regrutacijaFaza 4
- Sylvester Comprehensive Cancer Center, Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building, Miami
- University of Miami Hospital and Clinics, Miami
FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease
U tijeku regrutacija
- University of Miami, Miami
Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions
U tijeku regrutacijaOpažajna studija
- University of Miami Hospitals, Miami
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
U tijeku regrutacijaFaza 1/2
- University of Miami, Miami
- Miami Cancer Institute, Miami
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- University of Miami, Miami
Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
U tijeku regrutacijaFaza 2
- University of Miami, Miami
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 2
- University of Miami, Sylvester Comprehensive Cancer Center, Miami
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
- Miami Cancer Institute, Miami
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
U tijeku regrutacijaFaza 2
- University of Miami, Miami
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
U tijeku regrutacijaFaza 1
- Sylvester Comprehensive Cancer Center, University of Miami Hospital and Clinics, Miami
Studije za Multipli mijelom u drugim gradovima
- New York City, NY60 studija
- Boston, MA42 studija
- Atlanta, GA41 studija
- Houston, TX38 studija
- Durham, NC37 studija
- Nashville, TN32 studija
- Denver, CO27 studija
- Rochester, MN24 studija
- St. Louis, MO24 studija
- Columbus, OH24 studija
- Baldwin Park, CA23 studija
- Chicago, IL22 studija
Ostale studije u gradu Miami
- Rak dojke42 studija
- Rak (sve vrste)36 studija
- Nemikrocelularni karcinom pluća31 studija
- Rak prostate27 studija
- Debljina27 studija
- Akutna mijeloična leukemija24 studija
- Metastatski karcinom24 studija
- Rak jajnika23 studija
- Prekomjerna tjelesna masa23 studija
- Ulcerativni kolitis21 studija
- Alzheimerova bolest20 studija
- Rak pluća20 studija
Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.